Raphael Pharmaceutical Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Cautionary Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K, or the Annual Report, contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, which includes information relating to future events, future financial performance, financial projections, strategies, expectations, competitive environment and regulation. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:
| ● | the regulatory pathways that we may elect to utilize in seeking U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA, and other regulatory approvals, if any; |
| ● | obtaining (and the cost thereof) FDA and EMA approval of, or other regulatory action in Europe or the United States, or U.S., and elsewhere with respect to our product candidates; |
| ● | the commercial launch and future sales of our product candidates and our advancement of product candidates for other indications in our pipeline; |
| ● | the potential cost of our rheumatoid arthritis product candidate, or RA, and RA product candidate, respectively, for patients; |
| ● | our expectations regarding the timing of conducting clinical trials; |
| ● | our expectations regarding the supply of the active pharmaceutical ingredient for our product candidates; |
| ● | third-party payor reimbursement for our product candidates; |
| ● | our estimates regarding anticipated expenses, capital requirements and our needs for additional financing; |
| ● | completion and receiving favorable results of clinical trials for our product candidates; and |
| ● | the filing by us, and the subsequent issuance of patents to us, by the U.S. Patent and Trademark Office, or USPTO, and other governmental patent agencies. |
The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see “Item 1A. Risk Factors” for additional risks that could adversely impact our business and financial performance.
In this Annual Report, unless otherwise specified, all dollar amounts are expressed in U.S. dollars. Except as otherwise indicated by the context, references in this Annual Report to “Raphael,” “Company”, “we,” “us” and “our” are references to Raphael Pharmaceutical Inc., a Nevada corporation, together with its consolidated subsidiaries.
ii
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.